Laidlaw analyst Yale Jen initiated coverage of Nasus Pharma (NSRX) with a Buy rating and $22 price target The firm says Nasus is a mid-clinical stage biotech company focusing on the development of NS-002, a “well differentiated” powder-based intranasal anaphylaxis treatment. The “compelling” NS-002 in anaphylaxis Phase II study outcomes bode well for a successful Phase III study and potential approval as the first powder-based intranasal anaphylaxis therapy, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSRX:
- Opening Day: Fitness Champs makes public debut in slow IPO week
- Nasus Pharma Appoints CEO Dan Teleman to Board Amid Governance Changes
- Opening Day: Bullish has extremely bullish first day of trading
- Nasus Pharma Closes $10 Million IPO, Begins Trading on NYSE
- Nasus Pharma 1.25M share IPO priced at $8.00